Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASENSUS SURGICAL, INC.TRXC · Entity 88098 | EVP and CFO | May 13, 2019 | May 15, 2019 |
| CVRx, Inc.CVRX · Entity 6920 | Director | June 01, 2026 | June 03, 2026 |
| ImageneBio, Inc.IMA · Entity 7139 | Director | June 16, 2026 | June 18, 2026 |
| Omega Alpha SPACOMEG · Entity 143846 | Director | January 06, 2021 | January 06, 2021 |
| Replimune Group, Inc.REPL · Entity 4707 | Director | April 01, 2026 | April 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASENSUS SURGICAL, INC.
Report date May 13, 2019 · Filed May 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,000 |
Reported balance
After 2019-05-13 transaction · row 1
1 source rowRow 1 · 2019-05-13 · Exercise / conversion · Acquired 100,000 · Balance 100,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2028-02-07 | Direct | 674,708 |
Reported balance
After 2019-05-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-05-13 · Exercise / conversion · Disposed 100,000 · Balance 674,708 |
| Common StockSEC Table I · non-derivative | IndirectBy IRA | 25,000 |
Reported balance
Holding disclosure · report date 2019-05-13 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 25,000 |
CVRx, Inc.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,365 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 8,720 · Balance 39,365 F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.43 · Expires 2036-06-01 | Direct | 11,182 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Grant · Acquired 11,182 · Balance 11,182 F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.
ImageneBio, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.45 · Expires 2036-06-16 | Direct | 15,600 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 15,600 · Balance 15,600 F1: The shares vest in full upon the earlier to occur of the first anniversary of the date of grant, the date of the Issuer's next annual meeting or a change of control as defined in the Issuer's 2025 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest in full upon the earlier to occur of the first anniversary of the date of grant, the date of the Issuer's next annual meeting or a change of control as defined in the Issuer's 2025 Equity Incentive Plan.
Omega Alpha SPAC
Report date January 06, 2021 · Filed January 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table I · non-derivative | Direct | 35,000 |
Reported balance
Holding disclosure · report date 2021-01-06 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 35,000 F1: The Class B Ordinary Shares entitle the holder to one vote for each share held on all matters to be voted on by shareholders and will automatically convert into shares of Class A Ordinary Shares at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment, as described in the Issuer's registration statement on Form S-1 (File No. 333-251551). Class B Ordinary Shares have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Ordinary Shares entitle the holder to one vote for each share held on all matters to be voted on by shareholders and will automatically convert into shares of Class A Ordinary Shares at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment, as described in the Issuer's registration statement on Form S-1 (File No. 333-251551). Class B Ordinary Shares have no expiration date.
Replimune Group, Inc.
Report date April 01, 2026 · Filed April 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.61 · Expires 2036-04-01 | Direct | 44,500 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 44,500 · Balance 44,500 F1: The shares underlying this option vest entirely on April 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest entirely on April 1, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Morphic Holding, Inc.
Report date August 16, 2024 · Filed August 20, 2024
Section 16 reporting ended · disclosed 2024-08-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 1
1 source rowRow 1 · 2024-08-16 · Disposition to issuer · Disposed 9,066 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2029-06-26 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-08-16 · Disposition to issuer · Disposed 24,000 · Balance 0 F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.96 · Expires 2030-06-18 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-16 · Disposition to issuer · Disposed 12,000 · Balance 0 F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.79 · Expires 2031-06-16 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-08-16 · Disposition to issuer · Disposed 9,615 · Balance 0 F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2032-06-08 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-08-16 · Disposition to issuer · Disposed 17,550 · Balance 0 F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.47 · Expires 2033-05-31 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-08-16 · Disposition to issuer · Disposed 12,535 · Balance 0 F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.52 · Expires 2034-06-03 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-08-16 · Disposition to issuer · Disposed 23,168 · Balance 0 F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F5: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.
F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.
F3: The Company Stock Option ("Option") is fully vested.
F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.
F5: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 22:45 UTC | ImageneBio, Inc. IMA · Entity 7139 | GrantStock Option (right to buy) · Derivative | 15,600 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001246530-26-000004 · form4-06182026_060603.xml · derivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,600 Underlying: Common Stock · 15,600 shares Expires 2036-06-16 F1 · derivative.exercise_date: The shares vest in full upon the earlier to occur of the first anniversary of the date of grant, the date of the Issuer's next annual meeting or a change of control as defined in the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 22:05 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 11,182 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001246530-26-000002 · form4-06032026_100653.xml · derivative · entry 2 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,182 Underlying: Common Stock · 11,182 shares Expires 2036-06-01 F1 · derivative.exercise_date: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 22:05 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantCommon Stock | 8,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001246530-26-000002 · form4-06032026_100653.xml · nonDerivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,365 F1 · shares: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders. Read SEC document |
| April 01, 2026 Filed Apr 8, 2026 01:08 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 44,500 | $0.00 Strike: $7.61 | $0.00 |
DisclosureSEC source: 0001104659-26-040568 · tm2611350-3_4seq1.xml · derivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,500 Underlying: Common Stock · 44,500 shares Expires 2036-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2027. Read SEC document |
| December 24, 2025 Filed Dec 29, 2025 21:46 UTC | ImageneBio, Inc. IMA · Entity 7139 | PurchaseCommon Stock | 16,000 | $5.99 | $95,840.00 |
DisclosureSEC source: 0001246530-25-000007 · form4-12292025_091224.xml · nonDerivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Read SEC document |
| December 18, 2025 Filed Dec 22, 2025 22:10 UTC | ImageneBio, Inc. IMA · Entity 7139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 31,200 | $0.00 Strike: $6.19 | $0.00 |
DisclosureSEC source: 0001246530-25-000006 · form4-12222025_101250.xml · derivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,200 Underlying: Common Stock · 31,200 shares Expires 2035-12-18 F1 · security: The award was granted as an Initial Grant as contemplated by the non-employee director compensation policy adopted by the Issuer's board of directors on December 18, 2025. F2 · derivative.exercise_date: This option vests over a three-year period, with 1/36th of the shares subject to the option vesting in 36 substantially equal monthly installments, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan) through each such date. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:19 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 19,554 | $0.00 Strike: $6.76 | $0.00 |
DisclosureSEC source: 0001415889-25-015809 · form4-06052025_090603.xml · derivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,554 Underlying: Common Stock · 19,554 shares Expires 2035-06-03 F1 · derivative.exercise_date: Vests on the earlier of June 3, 2026 or the Issuer's 2026 annual meeting of stockholders. Read SEC document |
| April 01, 2025 Filed Apr 4, 2025 00:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001104659-25-031830 · tm2511407-6_4seq1.xml · derivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2035-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2026. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:12 UTC | Morphic Holding, Inc. MORF · Entity 88114 | Disposition to issuerStock Option (Right to Buy) · Derivative | 23,168 | Not disclosed Strike: $30.52 | Not disclosed |
DisclosureSEC source: 0001415889-24-021769 · form4-08202024_110810.xml · derivative · entry 7 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,168 shares Expires 2034-06-03 F4 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F5 · derivative.exercise_date: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:12 UTC | Morphic Holding, Inc. MORF · Entity 88114 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,535 | Not disclosed Strike: $56.47 | Not disclosed |
DisclosureSEC source: 0001415889-24-021769 · form4-08202024_110810.xml · derivative · entry 6 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,535 shares Expires 2033-05-31 F4 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3 · derivative.exercise_date: The Company Stock Option ("Option") is fully vested. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:12 UTC | Morphic Holding, Inc. MORF · Entity 88114 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,550 | Not disclosed Strike: $24.49 | Not disclosed |
DisclosureSEC source: 0001415889-24-021769 · form4-08202024_110810.xml · derivative · entry 5 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,550 shares Expires 2032-06-08 F4 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3 · derivative.exercise_date: The Company Stock Option ("Option") is fully vested. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:12 UTC | Morphic Holding, Inc. MORF · Entity 88114 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,615 | Not disclosed Strike: $64.79 | Not disclosed |
DisclosureSEC source: 0001415889-24-021769 · form4-08202024_110810.xml · derivative · entry 4 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,615 shares Expires 2031-06-16 F4 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3 · derivative.exercise_date: The Company Stock Option ("Option") is fully vested. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:12 UTC | Morphic Holding, Inc. MORF · Entity 88114 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,000 | Not disclosed Strike: $22.96 | Not disclosed |
DisclosureSEC source: 0001415889-24-021769 · form4-08202024_110810.xml · derivative · entry 3 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2030-06-18 F4 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3 · derivative.exercise_date: The Company Stock Option ("Option") is fully vested. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:12 UTC | Morphic Holding, Inc. MORF · Entity 88114 | Disposition to issuerStock Option (Right to Buy) · Derivative | 24,000 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001415889-24-021769 · form4-08202024_110810.xml · derivative · entry 2 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2029-06-26 F4 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3 · derivative.exercise_date: The Company Stock Option ("Option") is fully vested. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:12 UTC | Morphic Holding, Inc. MORF · Entity 88114 | Disposition to issuerCommon Stock | 9,066 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021769 · form4-08202024_110810.xml · nonDerivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · price: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. Read SEC document |
| August 15, 2024 Filed Aug 15, 2024 23:18 UTC | CVRx, Inc. CVRX · Entity 6920 | PurchaseCommon Stock | 3,000 | $8.10 | $24,300.00 |
DisclosureSEC source: 0001415889-24-021415 · form4-08152024_110829.xml · nonDerivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,645 Read SEC document |
| August 08, 2024 Filed Aug 8, 2024 20:18 UTC | CVRx, Inc. CVRX · Entity 6920 | PurchaseCommon Stock | 3,000 | $8.24 | $24,715.80 |
DisclosureSEC source: 0001415889-24-020981 · form4-08082024_080802.xml · nonDerivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,645 Read SEC document |
| August 06, 2024 Filed Aug 6, 2024 20:43 UTC | CVRx, Inc. CVRX · Entity 6920 | PurchaseCommon Stock | 2,500 | $9.09 | $22,725.00 |
DisclosureSEC source: 0001415889-24-020841 · form4-08062024_080850.xml · nonDerivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,645 Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 23:13 UTC | Morphic Holding, Inc. MORF · Entity 88114 | GrantCommon Stock · Derivative | 23,168 | $0.00 Strike: $30.52 | $0.00 |
DisclosureSEC source: 0001415889-24-015669 · form4-06052024_110631.xml · derivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,168 Underlying: Common Stock · 23,168 shares Expires 2034-06-03 F1 · derivative.exercise_date: The option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 23:07 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 20,961 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0001415889-24-015849 · form4-06062024_110613.xml · derivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,961 Underlying: Common Stock · 20,961 shares Expires 2034-06-04 F1 · derivative.exercise_date: Vests on the earlier of June 4, 2025 or the Issuer's 2025 annual meeting of stockholders. Read SEC document |
| June 04, 2024 Filed Jun 7, 2024 21:18 UTC Amendment | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 27,250 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0001415889-24-016037 · form4a-06072024_090606.xml · derivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,250 Underlying: Common Stock · 27,250 shares Expires 2034-06-04 F1 · shares: The reporting person's Form 4 filed on June 6, 2024 inadvertently understated the reporting person's stock options granted by 6,289. F2 · derivative.exercise_date: Vests on the earlier of June 4, 2025 or the Issuer's 2025 annual meeting of stockholders. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001104659-24-043252 · tm2410652-7_4seq1.xml · derivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2034-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2025. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 21:57 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionStock Option (right to buy) · Derivative | 96 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001415889-24-000059 · form4-01022024_090117.xml · derivative · entry 8 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,590 Underlying: Common Stock · 96 shares Expires 2029-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Vests as to 1/48th of the shares each month commencing August 24, 2019. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 21:57 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionStock Option (right to buy) · Derivative | 174 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001415889-24-000059 · form4-01022024_090117.xml · derivative · entry 7 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 174 shares Expires 2028-11-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 21:57 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionStock Option (right to buy) · Derivative | 1,456 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001415889-24-000059 · form4-01022024_090117.xml · derivative · entry 6 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,456 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 21:57 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionStock Option (right to buy) · Derivative | 224 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001415889-24-000059 · form4-01022024_090117.xml · derivative · entry 5 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 224 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 21:57 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionCommon Stock | 96 | $3.96 | $379.68 |
DisclosureSEC source: 0001415889-24-000059 · form4-01022024_090117.xml · nonDerivative · entry 4 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 21:57 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionCommon Stock | 174 | $1.19 | $206.36 |
DisclosureSEC source: 0001415889-24-000059 · form4-01022024_090117.xml · nonDerivative · entry 3 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 21:57 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionCommon Stock | 1,456 | $0.24 | $345.07 |
DisclosureSEC source: 0001415889-24-000059 · form4-01022024_090117.xml · nonDerivative · entry 2 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 21:57 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionCommon Stock | 224 | $0.24 | $53.09 |
DisclosureSEC source: 0001415889-24-000059 · form4-01022024_090117.xml · nonDerivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 00:04 UTC | Morphic Holding, Inc. MORF · Entity 88114 | PurchaseCommon Stock | 2,400 | $20.60 | $49,435.68 |
DisclosureSEC source: 0001209191-23-055236 · doc4.xml · nonDerivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,066 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.57 to $20.60 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 20:13 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 12,012 | $0.00 Strike: $12.33 | $0.00 |
DisclosureSEC source: 0001415889-23-009360 · form4-06072023_080648.xml · derivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,012 Underlying: Common Stock · 12,012 shares Expires 2033-06-04 F1 · derivative.exercise_date: Vests on the earlier of June 5, 2024 or the Issuer's 2024 annual meeting of stockholders. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 23:03 UTC | Morphic Holding, Inc. MORF · Entity 88114 | GrantDirector Stock Option (Right to Buy) · Derivative | 12,535 | $0.00 Strike: $56.47 | $0.00 |
DisclosureSEC source: 0001209191-23-034036 · doc4.xml · derivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,535 Underlying: Common Stock · 12,535 shares Expires 2033-05-31 F1 · derivative.exercise_date: The option will vest in full on the earlier of (a) June 1, 2024 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:03 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 25,200 | $0.00 Strike: $17.66 | $0.00 |
DisclosureSEC source: 0001104659-23-041732 · tm2311410-12_4seq1.xml · derivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,200 Underlying: Common Stock · 25,200 shares Expires 2033-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2024. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 23:00 UTC | Morphic Holding, Inc. MORF · Entity 88114 | GrantDirector Stock Option (Right to Buy) · Derivative | 17,550 | $0.00 Strike: $24.49 | $0.00 |
DisclosureSEC source: 0001209191-22-036117 · doc4.xml · derivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,550 Underlying: Common Stock · 17,550 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option will vest in full on the earlier of (a) June 8, 2023 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:35 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 26,985 | $0.00 Strike: $6.76 | $0.00 |
DisclosureSEC source: 0001415889-22-006363 · form4-06092022_010657.xml · derivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,985 Underlying: Common Stock · 26,985 shares Expires 2032-06-06 F1 · derivative.exercise_date: Vests on the earlier of June 7, 2023 or the Issuer's 2023 annual meeting of stockholders. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:11 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $18.26 | $0.00 |
DisclosureSEC source: 0001104659-22-042756 · tm2211665-10_4seq1.xml · derivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2032-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2023. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 22:47 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionStock Option (right to buy) · Derivative | 584 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001415889-22-000613 · form4-01182022_020120.xml · derivative · entry 24 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174 Underlying: Common Stock · 584 shares Expires 2028-11-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 22:47 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionStock Option (right to buy) · Derivative | 758 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001415889-22-000613 · form4-01182022_020120.xml · derivative · entry 23 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 758 shares Expires 2027-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 22:47 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionStock Option (right to buy) · Derivative | 316 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001415889-22-000613 · form4-01182022_020120.xml · derivative · entry 22 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 316 shares Expires 2025-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 22:47 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionStock Option (right to buy) · Derivative | 189 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001415889-22-000613 · form4-01182022_020120.xml · derivative · entry 21 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 189 shares Expires 2025-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 22:47 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionStock Option (right to buy) · Derivative | 189 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001415889-22-000613 · form4-01182022_020120.xml · derivative · entry 20 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 189 shares Expires 2025-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 22:47 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionStock Option (right to buy) · Derivative | 189 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001415889-22-000613 · form4-01182022_020120.xml · derivative · entry 19 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 189 shares Expires 2025-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 22:47 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionStock Option (right to buy) · Derivative | 189 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001415889-22-000613 · form4-01182022_020120.xml · derivative · entry 18 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 189 shares Expires 2025-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 22:47 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionStock Option (right to buy) · Derivative | 2,528 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001415889-22-000613 · form4-01182022_020120.xml · derivative · entry 17 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,528 shares Expires 2025-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 22:47 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionStock Option (right to buy) · Derivative | 316 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001415889-22-000613 · form4-01182022_020120.xml · derivative · entry 16 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · Not disclosed shares Expires 2024-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 22:47 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionStock Option (right to buy) · Derivative | 316 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001415889-22-000613 · form4-01182022_020120.xml · derivative · entry 15 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 316 shares Expires 2023-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 22:47 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionStock Option (right to buy) · Derivative | 3,917 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001415889-22-000613 · form4-01182022_020120.xml · derivative · entry 14 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,456 Underlying: Common Stock · 3,917 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 22:47 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionStock Option (right to buy) · Derivative | 2,149 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001415889-22-000613 · form4-01182022_020120.xml · derivative · entry 13 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224 Underlying: Common Stock · 2,149 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 22:47 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionCommon Stock | 584 | $1.19 | $692.62 |
DisclosureSEC source: 0001415889-22-000613 · form4-01182022_020120.xml · nonDerivative · entry 12 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.